MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

    Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…
  • 2018 International Congress

    The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America

    W. Oertel, H. Müller, C. Schade-Brittinger, C. Kamp, K. Balthasar, K. Articus, M. Brinkman, C. Venuto, M. Unger, K. Eggert, D. Vadasz, K. Kieburtz, J. Boyd (Marburg, Germany)

    Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…
  • 2018 International Congress

    Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

    D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

    Objective: This four-week open-label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free-living motor symptom monitoring…
  • 2018 International Congress

    Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion

    K. Kashihara, M. Kitayama (Okayama, Japan)

    Objective: To determine characteristics of parkinsonian patients under levodopa/carbidopa intestinal gel (LCIG) infusion who present impulse control disorders (ICDs). Background: ICDs may be induced by…
  • 2018 International Congress

    Speech Intelligibility in Parkinson’s disease following Intensive Voice and Articulation Treatments

    G. Schulz, A. Halpern, J. Spielman, L. Ramig, I. Panzer, A. Sharpley, H. Hodges (Silver Spring, MD, USA)

    Objective: Our aim was to evaluate the impact of voice treatment (LSVT LOUD) and articulation treatment (LSVT ARTIC) on speech and consonant intelligibility in Parkinson's…
  • 2018 International Congress

    A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients

    M. Winterholler, H. Erxleben (Schwarzenbruck, Germany)

    Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…
  • 2018 International Congress

    Persistent downbeat nystagmus due to Arnold-Chiari type I malformation

    W. Chen, L. Zhao, Q. He, L. Wu, R. Dong (Shanghai, China)

    Objective: Describe a patient with persistent downbeat nystagmus(DBN) related to Arnold-Chiari type I malformation Background: As a rare acquired nystagmus with various causes, DBN is…
  • 2018 International Congress

    Pediatric Tics and DCD: Motor Network Disorders?

    M. Kuiper, R. Brandsma, W. Eggink, M. Egmond, J. de Vries, P. Hoekstra, A. Dietrich, D. Sival (Groningen, Netherlands)

    Objective: To characterize and quantify pediatric tics and DCD according to specific movement disorder features. Background: Until now, it has been impossible to attribute the…
  • 2018 International Congress

    Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease

    D. Bega, J. Bronstein, D. Nicholl, F. Askari, A. Ala, P. Ferenci, C. Bjartmar, KH. Weiss, M. Schilsky, A. Czlonkowska (Chicago, IL, USA)

    Objective: The objective of this study was to characterize neurological manifestations in Wilson Disease (WD) patients and describe specific neurological changes after 24 weeks’ treatment…
  • 2018 International Congress

    Deep brain stimulation outcomes for primary and secondary dystonia

    M. Carmona-Abellán, O. Parras, R. Valentí, J. Guridi, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

    Objective: To describe clinical outcomes of pallidal stimulation in different types of dystonia, both primary and secondary and long-term results. Background: Many studies have previously…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24752 (not found)
  • An atypical and interesting feature of Parkinson´s disease
  • Fasciculations from a cholinesterase inhibitor
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley